Autres langues Progyny, Inc.

Actions

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/04/2024			Varia. 5j.	Varia. 1 janv.
32,4 ^USD	-2,00 %		-2,96 %	-12,86 %

12/03	Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
05/03	Un initié de Progyny a vendu des actions pour une valeur de 403 260 $, selon un récent dépôt auprès de la SEC	MT

Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care	17/04
Delta named one of Fortune's 100 Best Companies to Work For	04/04
Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast	04/04
Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum	18/03
Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference	11/03
Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing	05/03
Progyny Announces $100 Million Share Repurchase Program; Shares Rise	29/02
Progyny, Inc. Announces Share Repurchase Program	29/02
Progyny, Inc. Announces Share Repurchase Program	29/02
Progyny, Inc. announces an Equity Buyback for $100 million worth of its shares.	29/02
Progyny, Inc. authorizes a Buyback Plan.	29/02
Progyny Shares Slump After Q4 Results	28/02
North American Morning Briefing : Stock Futures Fall Ahead of Key Inflation Data	28/02
Progyny Q4 Adjusted Earnings, Revenue Rise	28/02
Progyny: Q4 Earnings Snapshot	27/02
Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024	27/02
Earnings Flash (PGNY) PROGYNY Reports Q4 EPS $0.32, vs. Street Est of $0.12	27/02
Earnings Flash (PGNY) PROGYNY Reports Q4 Revenue $269.9M, vs. Street Est of $274.1M	27/02
(PGNY) PROGYNY Forecasts Fiscal Year 2024 EPS $1.54 - $1.59	27/02
Progyny, Inc. Announces Fourth Quarter 2023 Results	27/02

Aucun résultat pour cette recherche